[go: up one dir, main page]

BR0211365A - Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica - Google Patents

Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica

Info

Publication number
BR0211365A
BR0211365A BR0211365-1A BR0211365A BR0211365A BR 0211365 A BR0211365 A BR 0211365A BR 0211365 A BR0211365 A BR 0211365A BR 0211365 A BR0211365 A BR 0211365A
Authority
BR
Brazil
Prior art keywords
weight gain
inhibiting
kit
patient receiving
receptor antagonist
Prior art date
Application number
BR0211365-1A
Other languages
English (en)
Inventor
Joseph K Belanoff
Alan F Schatzberg
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of BR0211365A publication Critical patent/BR0211365A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODO E KIT PARA INIBIR OU REVERTER O GANHO DE PESO EM UM PACIENTE SENDO TRATADO COM UMA MEDICAçãO ANTIPSICóTICA". Esta invenção pertence, genericamente, ao campo da psiquiatria. Em particular, esta invenção pertence à verificação de que, agentes capazes de inibir a ligação do cortisol a seus receptores, podem ser usados em métodos para impedir ganho de peso induzido por antipsicótico. A mifepristona, um potente antagonista de receptor de glicocorticóide específico, pode ser usada nestes métodos. A invenção também provê um kit para prevenir o ganho de peso induzido por AP em um humano, incluindo um antagonista de receptor de glicocorticóide e material instrucional dando as indicações, dosagem e programa de administração do antagonista de receptor de glicocorticóide.
BR0211365-1A 2001-07-23 2002-07-22 Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica BR0211365A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30769301P 2001-07-23 2001-07-23
PCT/US2002/023441 WO2003009853A1 (en) 2001-07-23 2002-07-22 Methods for preventing antipsychotic-induced weight gain

Publications (1)

Publication Number Publication Date
BR0211365A true BR0211365A (pt) 2004-09-21

Family

ID=23190816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211365-1A BR0211365A (pt) 2001-07-23 2002-07-22 Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica

Country Status (19)

Country Link
US (1) US6680310B2 (pt)
EP (1) EP1408981B1 (pt)
JP (2) JP2004537563A (pt)
KR (1) KR20040028942A (pt)
CN (2) CN1547473A (pt)
AT (1) ATE406166T1 (pt)
AU (1) AU2002319665B2 (pt)
BR (1) BR0211365A (pt)
CA (1) CA2454339C (pt)
CY (1) CY1108562T1 (pt)
DE (1) DE60228579D1 (pt)
DK (1) DK1408981T3 (pt)
ES (1) ES2312598T3 (pt)
IL (1) IL159913A0 (pt)
MX (1) MXPA04000692A (pt)
NZ (1) NZ530724A (pt)
PT (1) PT1408981E (pt)
WO (1) WO2003009853A1 (pt)
ZA (1) ZA200400444B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001893A (es) * 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
RU2674983C1 (ru) * 2013-11-25 2018-12-14 Корсепт Терапеутикс, Инк. Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
KR102342620B1 (ko) 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
WO2018227248A1 (en) * 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
SG11202105770YA (en) 2018-12-19 2021-07-29 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US20220288091A1 (en) 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
EP4072556A4 (en) * 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated METHODS OF TREATING ANTIPSYCHOTIC DRUG-INDUCED WEIGHT GAIN WITH MIRICORILANT
CN115515569A (zh) * 2020-05-06 2022-12-23 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂的制剂
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN119997939A (zh) 2022-10-06 2025-05-13 科赛普特治疗公司 糖皮质激素受体调节剂的制剂
CN120202004A (zh) 2022-10-28 2025-06-24 科赛普特治疗学股份有限公司 使用达祖可兰治疗肌萎缩侧索硬化症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
CN1528315A (zh) * 1997-10-06 2004-09-15 ������˹̹�������ѧ�й�ίԱ�� 治疗糖皮质素功能失调相关性精神病的方法
CN1130200C (zh) 1998-05-15 2003-12-10 利兰·斯坦福青年大学托管委员会 用于治疗痴呆的糖皮质激素受体拮抗剂
WO2000071106A2 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain

Also Published As

Publication number Publication date
DK1408981T3 (da) 2009-01-12
JP2004537563A (ja) 2004-12-16
AU2002319665B2 (en) 2006-09-21
ATE406166T1 (de) 2008-09-15
IL159913A0 (en) 2004-06-20
HK1061526A1 (en) 2004-09-24
EP1408981A4 (en) 2005-06-08
MXPA04000692A (es) 2004-04-21
PT1408981E (pt) 2008-12-04
US6680310B2 (en) 2004-01-20
JP2009102413A (ja) 2009-05-14
EP1408981A1 (en) 2004-04-21
DE60228579D1 (de) 2008-10-09
CN1853722A (zh) 2006-11-01
EP1408981B1 (en) 2008-08-27
ZA200400444B (en) 2005-03-30
ES2312598T3 (es) 2009-03-01
NZ530724A (en) 2005-09-30
CY1108562T1 (el) 2014-04-09
CA2454339C (en) 2012-01-10
KR20040028942A (ko) 2004-04-03
CN1547473A (zh) 2004-11-17
CA2454339A1 (en) 2003-02-06
US20030027802A1 (en) 2003-02-06
WO2003009853A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
BR0211365A (pt) Método e kit para inibir ou reverter o ganho de peso em um paciente sendo tratado com uma medicação antipsicótica
IL139672A0 (en) Glucocorticoid receptor antagonists for the treatment of dementia
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
NO20003534D0 (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
TR200700134T1 (tr) Sapogenin türevleri, bunların sentezi ve kullanımı, bunların kullanım metotları.
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
IL160649A0 (en) Methods for inhibiting cognitive deterioration in adults with down syndrome
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
MX2007003545A (es) Composiciones y metodos para tratar trastornos cognitivos.
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
DK1165184T3 (da) Estrogenreceptor-beta antagonisme og knoglesygdomme
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/56, A61P 25/00

Ipc: A61K 31/56 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]